MapLight Cash from 2010 to 2026
| MPLT Stock | 17.27 0.15 0.86% |
Cash | First Reported 2010-12-31 | Previous Quarter 44 M | Current Value 53.4 M | Quarterly Volatility 13.9 M |
Check MapLight Therapeutics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among MapLight Therapeutics' main balance sheet or income statement drivers, such as Depreciation And Amortization of 671.4 K, Selling General Administrative of 9.6 M or Other Operating Expenses of 62.9 M, as well as many indicators such as Price To Sales Ratio of 0.0, Dividend Yield of 0.0 or PTB Ratio of 7.21. MapLight financial statements analysis is a perfect complement when working with MapLight Therapeutics Valuation or Volatility modules.
MapLight | Cash | Build AI portfolio with MapLight Stock |
The evolution of Cash for MapLight Therapeutics Common provides essential context for understanding the company's financial health trajectory. By analyzing this metric's behavior over time, investors can assess whether recent trends align with long-term patterns, and how MapLight Therapeutics compares to historical norms and industry peers.
Latest MapLight Therapeutics' Cash Growth Pattern
Below is the plot of the Cash of MapLight Therapeutics Common over the last few years. Cash refers to the most liquid asset of MapLight Therapeutics, which is listed under current asset account on MapLight Therapeutics Common balance sheet and usually includes currency, coins, checking accounts, and not deposited checks received from MapLight Therapeutics customers. The amounts must be unrestricted with restricted cash listed in a different MapLight Therapeutics account. It is the total amount of money in the form of currency that a company has in its possession. This includes all bills, coins, and funds in bank accounts. MapLight Therapeutics' Cash historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in MapLight Therapeutics' overall financial position and show how it may be relating to other accounts over time.
| Cash | 10 Years Trend |
|
Cash |
| Timeline |
MapLight Cash Regression Statistics
| Arithmetic Mean | 33,828,030 | |
| Geometric Mean | 32,056,848 | |
| Coefficient Of Variation | 41.22 | |
| Mean Deviation | 9,425,811 | |
| Median | 27,665,000 | |
| Standard Deviation | 13,944,097 | |
| Sample Variance | 194.4T | |
| Range | 52.1M | |
| R-Value | 0.57 | |
| Mean Square Error | 139.6T | |
| R-Squared | 0.33 | |
| Significance | 0.02 | |
| Slope | 1,579,309 | |
| Total Sum of Squares | 3111T |
MapLight Cash History
Other Fundumenentals of MapLight Therapeutics
| Cash And Short Term Investments | ||
| Change In Cash | ||
| Free Cash Flow | ||
| Total Cashflows From Investing Activities |
MapLight Therapeutics Cash component correlations
Click cells to compare fundamentals
About MapLight Therapeutics Financial Statements
MapLight Therapeutics shareholders use historical fundamental indicators, such as Cash, to determine how well the company is positioned to perform in the future. Although MapLight Therapeutics investors may analyze each financial statement separately, they are all interrelated. The changes in MapLight Therapeutics' assets and liabilities, for example, are also reflected in the revenues and expenses on on MapLight Therapeutics' income statement. Understanding these patterns can help investors time the market effectively. Please read more on our fundamental analysis page.
| Last Reported | Projected for Next Year | ||
| Cash | 44 M | 53.4 M | |
| Cash And Short Term Investments | 125.1 M | 79.3 M | |
| Change In Cash | -37.4 M | -35.5 M | |
| Free Cash Flow | -71.6 M | -75.2 M | |
| Total Cashflows From Investing Activities | -72.7 M | -69.1 M | |
| Other Non Cash Items | 1 M | 900.5 K | |
| Total Cash From Operating Activities | -70.9 M | -74.5 M | |
| Total Cash From Financing Activities | 135.8 M | 93.8 M | |
| End Period Cash Flow | 44 M | 53.4 M | |
| Begin Period Cash Flow | 91.7 M | 59.1 M | |
| Other Cashflows From Financing Activities | -2 M | -2.1 M | |
| Free Cash Flow Yield | (0.12) | (0.13) | |
| Operating Cash Flow Per Share | (2.19) | (2.30) | |
| Free Cash Flow Per Share | (2.21) | (2.32) | |
| Cash Per Share | 2.36 | 1.39 | |
| Capex To Operating Cash Flow | (0.01) | (0.01) | |
| EV To Operating Cash Flow | (8.31) | (8.73) | |
| EV To Free Cash Flow | (8.23) | (8.65) | |
| Price To Operating Cash Flows Ratio | (8.68) | (9.11) | |
| Price To Free Cash Flows Ratio | (8.59) | (9.02) | |
| Cash Ratio | 2.16 | 2.67 | |
| Cash Conversion Cycle | (895.99) | (940.79) | |
| Free Cash Flow Operating Cash Flow Ratio | 1.16 | 1.12 | |
| Cash Flow Coverage Ratios | (13.78) | (14.47) | |
| Price Cash Flow Ratio | (8.68) | (9.11) | |
| Cash Flow To Debt Ratio | (13.78) | (14.47) |
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for MapLight Stock Analysis
When running MapLight Therapeutics' price analysis, check to measure MapLight Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy MapLight Therapeutics is operating at the current time. Most of MapLight Therapeutics' value examination focuses on studying past and present price action to predict the probability of MapLight Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move MapLight Therapeutics' price. Additionally, you may evaluate how the addition of MapLight Therapeutics to your portfolios can decrease your overall portfolio volatility.